CG Oncology (NASDAQ:CGON) Director James Mulay Sells 15,600 Shares of Stock

CG Oncology, Inc. (NASDAQ:CGON) Director James Mulay sold 15,600 shares of the business’s stock in a transaction dated Friday, April 17th. The stock was sold at an average price of $73.01, for a total value of $1,138,956.00. Following the transaction, the director directly owned 15,600 shares of the company’s stock, valued at approximately $1,138,956. This represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

James Mulay also recently made the following trade(s):

• On Monday, March 16th, James Mulay sold 1,964 shares of CG Oncology stock. The shares were sold at an average price of $63.50, for a total transaction of $124,714.00.

CG Oncology Stock Down 4.1%

Shares of CG Oncology stock opened at $70.40 on Tuesday. CG Oncology, Inc. has a 52-week low of $19.91 and a 52-week high of $73.56. The company has a 50 day moving average of $62.71 and a 200 day moving average of $50.82. The company has a market capitalization of $5.94 billion, a P/E ratio of -34.01 and a beta of 0.70.

CG Oncology (NASDAQ:CGON) last posted its quarterly earnings results on Friday, February 27th. The company reported ($0.51) EPS for the quarter, topping the consensus estimate of ($0.61) by $0.10. The firm had revenue of $2.32 million for the quarter. As a group, research analysts anticipate that CG Oncology, Inc. will post -2.57 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

CGON has been the topic of several recent analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of CG Oncology in a report on Wednesday, January 21st. JPMorgan Chase & Co. boosted their price objective on shares of CG Oncology from $65.00 to $91.00 and gave the stock an “overweight” rating in a research report on Friday. Morgan Stanley set a $93.00 target price on shares of CG Oncology in a research report on Friday, January 9th. Piper Sandler lifted their price target on shares of CG Oncology from $55.00 to $70.00 and gave the stock an “overweight” rating in a research note on Friday, January 16th. Finally, HC Wainwright boosted their price target on shares of CG Oncology from $80.00 to $100.00 and gave the company a “buy” rating in a research report on Tuesday, April 7th. Eleven research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, CG Oncology currently has an average rating of “Moderate Buy” and an average target price of $79.00.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in CGON. Whittier Trust Co. of Nevada Inc. acquired a new stake in shares of CG Oncology in the fourth quarter valued at approximately $27,000. Strengthening Families & Communities LLC acquired a new position in shares of CG Oncology in the 3rd quarter valued at $40,000. Comerica Bank increased its holdings in shares of CG Oncology by 100.4% in the 4th quarter. Comerica Bank now owns 1,028 shares of the company’s stock valued at $43,000 after acquiring an additional 515 shares during the period. Picton Mahoney Asset Management purchased a new stake in CG Oncology in the 4th quarter valued at $118,000. Finally, Mirae Asset Global Investments Co. Ltd. raised its position in CG Oncology by 33.0% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,920 shares of the company’s stock valued at $163,000 after purchasing an additional 972 shares during the last quarter. Institutional investors and hedge funds own 26.56% of the company’s stock.

CG Oncology Company Profile

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.